ipharmacenter
@ipharmacenter
Followers
130
Following
132
Media
157
Statuses
3K
#iPharmaCenter is a #website which covers #pharmaceutical and #healthcare #news For #PR, #guestpost, consulting reports write to [email protected]
Varanasi
Joined April 2018
Find our #healthcare & #pharmaceutical #consulting services on #fiverr
https://t.co/yk94ymcNDC You can also write to info@ipharmacenter.com Our services include #Competitiveintelligence #Pipelinereports #Marketresearch #Marketaccess #Forecasting #news #media #pharma #freelance
fiverr.com
I am a healthcare consultant who can provide services for the following - Competitive Intelligence - Market research reports - Market access strategies -
0
5
6
#BREAKING - #SunPharma launches #UNLOXCYT in the #USA. This novel PD-L1 inhibitor offers a new hope for mCSCC and laCSCC Full story here https://t.co/iGAg0Al4vg
#Oncology #SkinCancer #PharmaNews #SunPharma #aCSCC #ASCO #OncoAlert #OncoTwitter #Oncology #innovation #CancerResearch
ipharmacenter.com
Sun Pharmaceutical Industries has introduced UNLOXCYT (cosibelimab) in the United States for adult patients diagnosed with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced...
0
0
0
#BREAKING - #SunPharma launches #UNLOXCYT in the#USA. This novel PD-L1 inhibitor offers a new hope for mCSCC and laCSCC Full story here https://t.co/iGAg0AlCkO
#Oncology #SkinCancer #PharmaNews #SunPharma #aCSCC #ASCO #OncoAlert #OncoTwitter #Oncology #innovation #CancerResearch
ipharmacenter.com
Sun Pharmaceutical Industries has introduced UNLOXCYT (cosibelimab) in the United States for adult patients diagnosed with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced...
0
0
0
#BRAFTOVI‑based combo raises the bar in BRAF V600E–mutant mCRC. Phase 3 BREAKWATER data from #ASCOGI26 show higher response rates https://t.co/jgReEMhsh6
#ASCOGI26 #ASCOGI #colorectalcancer #Oncotwitter #Oncology #OncoTwitter #BRAF #BRAFmutation #GIcancer #news #Breaking #media
ipharmacenter.com
Pfizer Braftovi -Based Combination Regimen With Enhanced Chemotherapy Backbone Boosts Response Rates in Select Patients With Metastatic Colorectal CancerPfizer has announced new Phase 3 data from the...
0
0
0
#MEDIA - The #pharmaceutical market in 2026 continues to be shaped by powerful forces across #oncology, #metabolicdisorders, and #immunology. https://t.co/8yV38RzRdi
#pharma #pharmaceutical #breakingnews #news #media #OncoTwitter #Oncology #cancer
ipharmacenter.com
Top-Selling Drugs of 2026: Oncology, Diabetes, and Immunology Take the LeadThe pharmaceutical market in 2026 continues to be shaped by powerful forces across oncology, metabolic disorders, and...
0
0
0
#Astellas presented the long-term growth strategy at #JPM26 Find major updates of all companies in one place https://t.co/3PatfWeHlA
#news #media #pharma #pharmaceutical #JPMHC2026 #JPMHC26 #JPMHC2026 #JPMHC2026 #Japan #drugpricing #innovation #oncology #ASCOUpdates #OncoAlerts
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#EliLilly showcased its strategy to address massive patient populations across #obesity, #diabetes, obstructive sleep apnea, pain, #cardiovascular, #renal, and hepatic diseases at #JPM26
https://t.co/9VZP3Htoyr
#news #media #pharma #pharmaceutical #JPMHC2026 #JPMHC26
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#BREAKING: #BMS showed robust pipeline at #JPM2026
https://t.co/3PatfWeHlA
#news #media #pharma #pharmaceutical #JPMHC2026 #JPMHC26 #JPM26 #media #breakingnews #obesity #drugpricing #weightloss #Trump #PresidentTrump
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#BREAKING: #EliLilly Highlights Expansive Pipeline at #JPM2026, Targeting 1 Billion Patients in High-Volume Diseases https://t.co/9VZP3Htoyr
#news #media #pharma #pharmaceutical #JPMHC2026 #JPMHC26 #JPM26 #breakingnews #obesity #drugpricing #weightloss #trump #presidenttrump
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#BREAKING: #EliLilly Highlights Expansive Pipeline at #JPM2026, Targeting 1 Billion Patients in High-Volume Diseases https://t.co/9VZP3Htoyr
#news #media #pharma #pharmaceutical #JPMHC2026 #JPMHC26 #JPM26 #media #breakingnews #obesity #drugpricing #weightloss
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#Oncology, #diabetes, #obesity and #immunology continue to dominate pharma in 2026, with a handful of #blockbusters driving record global revenues across major markets https://t.co/8yV38RAp2Q
#TopDrugs #PharmaSales #biotech #innovation #biotech #jpmhc2026 #pharma #healthcare
ipharmacenter.com
Top-Selling Drugs of 2026: Oncology, Diabetes, and Immunology Take the LeadThe pharmaceutical market in 2026 continues to be shaped by powerful forces across oncology, metabolic disorders, and...
0
0
0
#Oncology, #diabetes, #obesity and #immunology continue to dominate pharma in 2026, with a handful of #blockbusters driving record global revenues across major markets https://t.co/QOFIVhgvN2
#TopDrugs #PharmaSales #biotech #innovation #biotech #jpmhc2026 #pharma #healthcare
0
0
0
#Roche is leaning hard into partnership‑driven growth, spotlighting #neurology, #oncology and cardiometabolic disease plus a deep late‑stage #pipeline to fuel long‑term expansion #PharmaNews #JPM2026 #pharma #news #media #JPM2026 #jpmhc2026
https://t.co/tBSDU6XlM8
0
0
0
#Roche betting on partnerships for growth Find more details here https://t.co/9VZP3Htoyr
#news #media #JPM26 #JPM #JPM2026 #pharma #pharmaceutical #media #Breaking #jpmhc26 #JPMHC
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
1
Find all #jpmhc26 updates at one place https://t.co/9VZP3Htoyr
#pharma #healthcare #trump #drugpricing $JPM
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#Merck forecast $70 billion by mid 2030s, 2x the revenues of KEYTRUDA at its peak Find more details here https://t.co/9VZP3Htoyr
#news #media #JPM26 #JPM #JPM2026 #pharma #pharmaceutical #media #Breaking #jpmhc26 #JPMHC
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#Merck used its #JPMorgan 2026 Healthcare Conference presentation to show how it plans to sustain growth as #Keytruda moves toward loss of exclusivity. https://t.co/9VZP3Htoyr
#news #media #JPM26 #JPM #JPM2026 #pharma #pharmaceutical #media #Breaking #jpmhc26
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#Novartis is concentrating its efforts on four main therapeutic pillars: cardiovascular‑renal‑metabolic disease, #immunology conditions, #neurological disorders, and #oncology
https://t.co/3PatfWeHlA
#news #media #JPM26 #JPM #JPM2026 #pharma #pharmaceutical #media #Breaking
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#Roche is using the #JPMorgan 2026 #Healthcare Conference to underline a partnership driven growth strategy built around #neurology, #oncology, and cardiometabolic disease https://t.co/9VZP3Htoyr
#news #media #JPM26 #JPM #JPM2026 #pharma #pharmaceutical #media #Breaking
ipharmacenter.com
RocheRoche is using the J.P. Morgan 2026 Healthcare Conference to underline a partnership driven growth strategy built around neurology, oncology, and cardiometabolic disease, with a deep late‑stage...
0
0
0
#Oncology, GLP-1s, & #immunology are set to dominate #pharma revenues in 2026. #Keytruda, #Mounjaro, #Skyrizi, #Dupixent, #Ozempic, #Wegovy and more pass the $10B mark. Dive into the full top-10 list https://t.co/8yV38RAp2Q
#BREAKING #news #media #healthcare #US #drugpricing
0
0
0
#Oncology, GLP-1s, & #immunology are set to dominate #pharma revenues in 2026. #Keytruda, #Mounjaro, #Skyrizi, #Dupixent, #Ozempic, #Wegovy and more pass the $10B mark. Dive into the full top-10 list https://t.co/8yV38RAp2Q
#BREAKING #news #media #healthcare #US #drugpricing
ipharmacenter.com
Top-Selling Drugs of 2026: Oncology, Diabetes, and Immunology Take the LeadThe pharmaceutical market in 2026 continues to be shaped by powerful forces across oncology, metabolic disorders, and...
0
0
0